Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...

Bristol-Myers Squibb’s KRAS inhibitor Krazati has been approved for a second indication, colorectal cancer (CRC), which could inject some much-needed sales growth into the product. The FDA has given ...

Bristol Myers Squibb added a big name to its executive roster with the appointment of Harald Hampel, M.D., Ph.D. as its new SVP and worldwide head of medical affairs, neuroscience. Hampel comes to BMS ...

Reviewing the detailed syllabus and question paper design is essential for students to prioritize high-weightage chapters, practice the exact typology of questions, and build a strategic study plan ...

Bristol-Myers Squibb (BMS) reported stronger-than-expected earnings for the fourth quarter of 2025, with earnings per share (EPS) reaching $1.26, surpassing the anticipated $1.12. Revenue also ...

Check the latest and revised syllabus for the CBSE board class 10th other subjects. Check the details below: Step 2: Click on the section labelled “Curriculum.” Step 3: Click on the link or tab ...

Bristol Myers Squibb (NYSE: BMY) today reported fourth quarter and full-year 2025 financial results. Visit the company’s Investor Relations website at http ...

The impending merger between Bristol-Myers Squibb (BMS) and Medarex marks the end of an era. Medarex is one of the last independent public biotech companies that built their businesses around ...